$EMMA
Emmaus Life Sciences, Inc.

2023 Q2 Form 10-Q Financial Statement

#000095017023021891 Filed on May 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $10.76M $6.753M $3.234M
YoY Change 150.97% 108.81% -39.38%
Cost Of Revenue $508.0K $429.0K $1.007M
YoY Change 28.28% -57.4% 130.96%
Gross Profit $10.25M $6.324M $2.227M
YoY Change 163.45% 183.97% -54.54%
Gross Profit Margin 95.28% 93.65% 68.86%
Selling, General & Admin $6.605M $7.200M $4.829M
YoY Change 31.23% 49.1% 2.64%
% of Gross Profit 64.43% 113.85% 216.84%
Research & Development $320.0K $289.0K $466.0K
YoY Change 7.38% -37.98% -74.24%
% of Gross Profit 3.12% 4.57% 20.93%
Depreciation & Amortization $9.000K $9.000K $11.00K
YoY Change -10.0% -18.18% -26.67%
% of Gross Profit 0.09% 0.14% 0.49%
Operating Expenses $6.925M $7.489M $5.295M
YoY Change 29.9% 41.44% -18.71%
Operating Profit $3.326M -$1.165M -$3.068M
YoY Change -330.97% -62.03% 89.97%
Interest Expense $1.793M $1.502M $737.0K
YoY Change 39.32% 103.8% -30.08%
% of Operating Profit 53.91%
Other Income/Expense, Net $173.0K $160.0K $222.0K
YoY Change 30.08% -27.93% 16.84%
Pretax Income -$1.516M -$3.478M -$1.645M
YoY Change -82.59% 111.43% -80.43%
Income Tax -$34.00K $49.00K -$103.0K
% Of Pretax Income
Net Earnings -$1.482M -$3.500M -$1.542M
YoY Change -83.33% 126.98% -81.69%
Net Earnings / Revenue -13.77% -51.83% -47.68%
Basic Earnings Per Share -$0.03 -$0.07 -$0.03
Diluted Earnings Per Share -$0.03 -$0.07 -$31.27K
COMMON SHARES
Basic Shares Outstanding 53.64M 50.93M 49.31M
Diluted Shares Outstanding 52.87M 50.71M 49.31M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.361M $1.774M $813.0K
YoY Change 38.59% 118.2% -78.37%
Cash & Equivalents $1.361M $1.774M $813.0K
Short-Term Investments
Other Short-Term Assets $434.0K $401.0K $379.0K
YoY Change 2.84% 5.8% 59.92%
Inventory $1.814M $2.216M $3.453M
Prepaid Expenses $337.0K $419.0K $399.0K
Receivables $5.573M $2.204M $938.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $9.847M $7.418M $6.448M
YoY Change 49.51% 15.04% -54.4%
LONG-TERM ASSETS
Property, Plant & Equipment $68.00K $72.00K $138.0K
YoY Change -20.0% -47.83% 26.61%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $18.30M $19.11M $41.29M
YoY Change 7.77% -53.73% -5.58%
Other Assets $276.0K $277.0K $297.0K
YoY Change 5.75% -6.73% 1.37%
Total Long-Term Assets $40.44M $41.53M $45.05M
YoY Change 2.63% -7.81% -6.32%
TOTAL ASSETS
Total Short-Term Assets $9.847M $7.418M $6.448M
Total Long-Term Assets $40.44M $41.53M $45.05M
Total Assets $50.29M $48.95M $51.49M
YoY Change 9.35% -4.95% -17.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.441M $4.733M $2.873M
YoY Change 14.43% 64.74% 105.36%
Accrued Expenses $8.956M $6.718M $6.085M
YoY Change 44.54% 10.4% 50.36%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $5.641M $7.663M
YoY Change -100.0% -26.39% -12.92%
Long-Term Debt Due $30.47M $23.01M $12.86M
YoY Change 48.94% 79.01% 178.49%
Total Short-Term Liabilities $61.55M $57.86M $34.55M
YoY Change 33.58% 67.45% 41.56%
LONG-TERM LIABILITIES
Long-Term Debt $3.416M $4.426M $4.650M
YoY Change -4.82% -61.87%
Other Long-Term Liabilities $18.13M $20.26M $31.51M
YoY Change -42.79% -35.71% -8.6%
Total Long-Term Liabilities $18.13M $20.26M $31.51M
YoY Change -42.79% -35.71% -8.6%
TOTAL LIABILITIES
Total Short-Term Liabilities $61.55M $57.86M $34.55M
Total Long-Term Liabilities $18.13M $20.26M $31.51M
Total Liabilities $85.32M $84.90M $73.79M
YoY Change 5.82% 15.05% 25.33%
SHAREHOLDERS EQUITY
Retained Earnings -$257.4M -$255.9M
YoY Change 2.08%
Common Stock $222.5M $222.9M
YoY Change 0.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$35.03M -$35.95M -$22.30M
YoY Change
Total Liabilities & Shareholders Equity $50.29M $48.95M $51.49M
YoY Change 9.35% -4.95% -17.24%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$1.482M -$3.500M -$1.542M
YoY Change -83.33% 126.98% -81.69%
Depreciation, Depletion And Amortization $9.000K $9.000K $11.00K
YoY Change -10.0% -18.18% -26.67%
Cash From Operating Activities -$1.305M -$1.292M -$4.733M
YoY Change 22.77% -72.7% 18.3%
INVESTING ACTIVITIES
Capital Expenditures $5.000K $6.000K $2.000K
YoY Change -131.25% 200.0%
Acquisitions
YoY Change
Other Investing Activities $1.069M -$1.085M $1.229M
YoY Change -165.34% -188.28% -169.47%
Cash From Investing Activities $1.064M -$1.091M $1.227M
YoY Change -164.41% -188.92% -169.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -153.0K 2.141M 2.056M
YoY Change -105.29% 4.13% -70.82%
NET CHANGE
Cash From Operating Activities -1.305M -1.292M -4.733M
Cash From Investing Activities 1.064M -1.091M 1.227M
Cash From Financing Activities -153.0K 2.141M 2.056M
Net Change In Cash -394.0K -247.0K -1.466M
YoY Change -321.35% -83.15% -215.25%
FREE CASH FLOW
Cash From Operating Activities -$1.305M -$1.292M -$4.733M
Capital Expenditures $5.000K $6.000K $2.000K
Free Cash Flow -$1.310M -$1.298M -$4.735M
YoY Change 25.12% -72.59%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000822370
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-35527
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
EMMAUS LIFE SCIENCES, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0419387
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
21250 Hawthorne Boulevard
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 800
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Torrance
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90503
CY2023Q1 dei City Area Code
CityAreaCode
310
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
214-0065
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 emma Long Term Notes Payable Excluding Convertible Long Term Notes Payable
LongTermNotesPayableExcludingConvertibleLongTermNotesPayable
380000
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
53637554
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1774000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2021000
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2204000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
375000
CY2023Q1 us-gaap Inventory Net
InventoryNet
2216000
CY2022Q4 us-gaap Inventory Net
InventoryNet
2379000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1224000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1514000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
7418000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
6289000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
72000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
75000
CY2023Q1 us-gaap Equity Method Investments
EquityMethodInvestments
19106000
CY2022Q4 us-gaap Equity Method Investments
EquityMethodInvestments
18828000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2646000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2799000
CY2023Q1 emma Investment In Convertible Bond
InvestmentInConvertibleBond
19427000
CY2022Q4 emma Investment In Convertible Bond
InvestmentInConvertibleBond
19971000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
277000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
263000
CY2023Q1 us-gaap Assets
Assets
48946000
CY2022Q4 us-gaap Assets
Assets
48225000
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
14423000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
13549000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
722000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
703000
CY2023Q1 emma Conversion Feature Derivative Note Payable
ConversionFeatureDerivativeNotePayable
3159000
CY2022Q4 emma Conversion Feature Derivative Note Payable
ConversionFeatureDerivativeNotePayable
3248000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
13972000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
12917000
CY2023Q1 us-gaap Derivative Instruments And Hedges Liabilities
DerivativeInstrumentsAndHedgesLiabilities
85000
CY2022Q4 us-gaap Derivative Instruments And Hedges Liabilities
DerivativeInstrumentsAndHedgesLiabilities
70000
CY2023Q1 emma Notes Payable Current Excluding Convertible Notes Payable Current
NotesPayableCurrentExcludingConvertibleNotesPayableCurrent
8325000
CY2022Q4 emma Notes Payable Current Excluding Convertible Notes Payable Current
NotesPayableCurrentExcludingConvertibleNotesPayableCurrent
6814000
CY2023Q1 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
2482000
CY2022Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
2367000
CY2023Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
14687000
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
14655000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
57855000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
54323000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2362000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2553000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
20256000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
21714000
CY2023Q1 emma Long Term Notes Payable Excluding Convertible Long Term Notes Payable
LongTermNotesPayableExcludingConvertibleLongTermNotesPayable
0
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
5295000
CY2023Q1 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
3426000
CY2022Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
3346000
CY2023Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
1000000
CY2023Q1 us-gaap Liabilities
Liabilities
84899000
CY2022Q4 us-gaap Liabilities
Liabilities
82316000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50934852
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50934852
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49583501
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49583501
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
51000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
50000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
222878000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
220815000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2977000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2619000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-255905000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-252337000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-35953000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-34091000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
48946000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
48225000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6753000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3234000
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
429000
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
1007000
CY2023Q1 us-gaap Gross Profit
GrossProfit
6324000
CY2022Q1 us-gaap Gross Profit
GrossProfit
2227000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
289000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
466000
CY2023Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2317000
CY2022Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1460000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4883000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3369000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
7489000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1165000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3068000
CY2023Q1 emma Gain Loss On Warrant Derivative Liabilities
GainLossOnWarrantDerivativeLiabilities
-14000
CY2022Q1 emma Gain Loss On Warrant Derivative Liabilities
GainLossOnWarrantDerivativeLiabilities
748000
CY2023Q1 emma Gain Loss On Conversion Feature Derivative Note Payable
GainLossOnConversionFeatureDerivativeNotePayable
89000
CY2022Q1 emma Gain Loss On Conversion Feature Derivative Note Payable
GainLossOnConversionFeatureDerivativeNotePayable
3080000
CY2022Q1 emma Gain Loss On Investment In Convertible Bond
GainLossOnInvestmentInConvertibleBond
-133000
CY2023Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-527000
CY2022Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-566000
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-519000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1191000
CY2023Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
160000
CY2022Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
222000
CY2023Q1 us-gaap Interest Expense
InterestExpense
1502000
CY2022Q1 us-gaap Interest Expense
InterestExpense
737000
CY2023Q1 emma Nonoperating Income Expense Including Income Loss From Equity Method Investments
NonoperatingIncomeExpenseIncludingIncomeLossFromEquityMethodInvestments
-2313000
CY2022Q1 emma Nonoperating Income Expense Including Income Loss From Equity Method Investments
NonoperatingIncomeExpenseIncludingIncomeLossFromEquityMethodInvestments
1423000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3478000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1645000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
49000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-103000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3527000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1542000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-544000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
350000
CY2022Q1 emma Other Comprehensive Income Loss Reclassification Adjustment For Loss Included In Net Income Loss
OtherComprehensiveIncomeLossReclassificationAdjustmentForLossIncludedInNetIncomeLoss
7000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
186000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
331000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-358000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
688000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3885000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-854000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50709627
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50709627
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49311864
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49311864
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-34091000
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
500000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
334000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1189000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-544000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
186000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3527000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-35953000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-21450000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
350000
CY2022Q1 emma Other Comprehensive Income Loss Reclassification Adjustment For Loss Included In Net Income Loss
OtherComprehensiveIncomeLossReclassificationAdjustmentForLossIncludedInNetIncomeLoss
7000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
331000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1542000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-22299000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-3527000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-1542000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
15000
CY2022Q1 emma Inventory Reserve
InventoryReserve
-794000
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
582000
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
411000
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-471000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-1205000
CY2022Q1 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
117000
CY2022Q1 us-gaap Debt Securities Realized Gain Loss
DebtSecuritiesRealizedGainLoss
-133000
CY2023Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-527000
CY2022Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-566000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1189000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5000
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
334000
CY2023Q1 emma Gain Loss On Warrant Derivative Liabilities
GainLossOnWarrantDerivativeLiabilities
-14000
CY2022Q1 emma Gain Loss On Warrant Derivative Liabilities
GainLossOnWarrantDerivativeLiabilities
748000
CY2023Q1 emma Gain Loss On Conversion Feature Derivative Note Payable
GainLossOnConversionFeatureDerivativeNotePayable
89000
CY2022Q1 emma Gain Loss On Conversion Feature Derivative Note Payable
GainLossOnConversionFeatureDerivativeNotePayable
3080000
CY2023Q1 emma Gain Loss On Option Instrument
GainLossOnOptionInstrument
-10000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1828000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-102000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-161000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-143000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-241000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-113000
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-186000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-160000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1001000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
530000
CY2023Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-545000
CY2022Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-2980000
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-28000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-443000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1292000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4733000
CY2022Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
2919000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000
CY2023Q1 emma Loan To Equity Method Investee
LoanToEquityMethodInvestee
-1085000
CY2022Q1 emma Loan To Equity Method Investee
LoanToEquityMethodInvestee
-1690000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1091000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1227000
CY2023Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
1484000
CY2022Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
20000
CY2023Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
227000
CY2022Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
2036000
CY2023Q1 emma Proceeds From Related Party Convertible Debt
ProceedsFromRelatedPartyConvertibleDebt
1000000
CY2023Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
520000
CY2023Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
50000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2141000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2056000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-5000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-16000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-247000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1466000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2021000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2279000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1774000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
813000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
276000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
212000
CY2023Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
1000
CY2022Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
4000
CY2023Q1 emma Renewal Of Notes Payable Including Interests Capitalized
RenewalOfNotesPayableIncludingInterestsCapitalized
926000
CY2023Q1 emma Conversion Of Convertible Note Payable To Common Stock
ConversionOfConvertibleNotePayableToCommonStock
500000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3500000
CY2023Q1 emma Working Capital Deficit
WorkingCapitalDeficit
50400000
CY2023Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
61174436
CY2022Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
23261199
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6753000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3234000
CY2022Q4 emma Revenue Allowance And Accrual Activities
RevenueAllowanceAndAccrualActivities
5491000
CY2023Q1 emma Revenue Allowance And Accrual Activities Provision Related To Sales In Current Year
RevenueAllowanceAndAccrualActivitiesProvisionRelatedToSalesInCurrentYear
1350000
CY2023Q1 emma Revenue Allowance And Accrual Activities Adjustments Related To Prior Period Sales
RevenueAllowanceAndAccrualActivitiesAdjustmentsRelatedToPriorPeriodSales
83000
CY2023Q1 emma Revenue Allowance And Accrual Activities Credit And Payments Made
RevenueAllowanceAndAccrualActivitiesCreditAndPaymentsMade
1463000
CY2023Q1 emma Revenue Allowance And Accrual Activities
RevenueAllowanceAndAccrualActivities
5295000
CY2021Q4 emma Revenue Allowance And Accrual Activities
RevenueAllowanceAndAccrualActivities
5154000
CY2022Q1 emma Revenue Allowance And Accrual Activities Provision Related To Sales In Current Year
RevenueAllowanceAndAccrualActivitiesProvisionRelatedToSalesInCurrentYear
893000
CY2022Q1 emma Revenue Allowance And Accrual Activities Adjustments Related To Prior Period Sales
RevenueAllowanceAndAccrualActivitiesAdjustmentsRelatedToPriorPeriodSales
44000
CY2022Q1 emma Revenue Allowance And Accrual Activities Credit And Payments Made
RevenueAllowanceAndAccrualActivitiesCreditAndPaymentsMade
1549000
CY2022Q1 emma Revenue Allowance And Accrual Activities
RevenueAllowanceAndAccrualActivities
4454000
CY2023Q1 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1362000
CY2022Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1393000
CY2023Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
280000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
513000
CY2023Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
5526000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
5428000
CY2023Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
4952000
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
4955000
CY2023Q1 us-gaap Inventory Net
InventoryNet
2216000
CY2022Q4 us-gaap Inventory Net
InventoryNet
2379000
CY2023Q1 us-gaap Prepaid Insurance
PrepaidInsurance
404000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
598000
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
419000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
467000
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
401000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
449000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1224000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1514000
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
511000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
505000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
439000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
430000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
72000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
75000
CY2023Q1 us-gaap Depreciation
Depreciation
9000
CY2022Q1 us-gaap Depreciation
Depreciation
11000
CY2020Q3 us-gaap Debt Instrument Call Date Earliest
DebtInstrumentCallDateEarliest
2020-09-28
CY2022Q1 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-126000
CY2022Q1 us-gaap Other Income
OtherIncome
41000
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
19971000
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
26100000
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
-2919000
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
-126000
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
-544000
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
-3084000
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
19427000
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
19971000
CY2023Q1 emma Clinical And Regulatory Expenses
ClinicalAndRegulatoryExpenses
393000
CY2022Q4 emma Clinical And Regulatory Expenses
ClinicalAndRegulatoryExpenses
361000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
652000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
626000
CY2023Q1 emma Accrued Selling Expenses
AccruedSellingExpenses
1756000
CY2022Q4 emma Accrued Selling Expenses
AccruedSellingExpenses
1363000
CY2023Q1 emma Accrued Manufacturing Expenses Current
AccruedManufacturingExpensesCurrent
1023000
CY2022Q4 emma Accrued Manufacturing Expenses Current
AccruedManufacturingExpensesCurrent
650000
CY2023Q1 emma Accrued Non Employee Board Member Compensation
AccruedNonEmployeeBoardMemberCompensation
552000
CY2022Q4 emma Accrued Non Employee Board Member Compensation
AccruedNonEmployeeBoardMemberCompensation
484000
CY2023Q1 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
357000
CY2022Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
301000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
4733000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3785000
CY2023Q1 emma Interest Payable Related Parties Current
InterestPayableRelatedPartiesCurrent
377000
CY2022Q4 emma Interest Payable Related Parties Current
InterestPayableRelatedPartiesCurrent
144000
CY2023Q1 us-gaap Interest Payable Current
InterestPayableCurrent
2595000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
2381000
CY2023Q1 emma Accrued Payroll Salary And Taxes Current
AccruedPayrollSalaryAndTaxesCurrent
1241000
CY2022Q4 emma Accrued Payroll Salary And Taxes Current
AccruedPayrollSalaryAndTaxesCurrent
1263000
CY2023Q1 emma Accrued Government Rebates And Other Rebates Current
AccruedGovernmentRebatesAndOtherRebatesCurrent
4973000
CY2022Q4 emma Accrued Government Rebates And Other Rebates Current
AccruedGovernmentRebatesAndOtherRebatesCurrent
5536000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
504000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
440000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6718000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7239000
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
14423000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
13549000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
13972000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
12917000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
20256000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
21714000
CY2023Q1 emma Debt Instrument Principal Outstanding Amount
DebtInstrumentPrincipalOutstandingAmount
32214000
CY2023Q1 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
2367000
CY2023Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
29920000
CY2023Q1 us-gaap Debt Instrument Convertible Number Of Equity Instruments
DebtInstrumentConvertibleNumberOfEquityInstruments
43028180
CY2022Q4 emma Debt Instrument Principal Outstanding Amount
DebtInstrumentPrincipalOutstandingAmount
30418000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
2918000
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
27562000
CY2022 us-gaap Debt Instrument Convertible Number Of Equity Instruments
DebtInstrumentConvertibleNumberOfEquityInstruments
41644749
CY2023Q1 us-gaap Debt Weighted Average Interest Rate
DebtWeightedAverageInterestRate
0.10
CY2022Q4 us-gaap Debt Weighted Average Interest Rate
DebtWeightedAverageInterestRate
0.08
CY2023Q1 emma Debt Weighted Average Effective Interest Rate
DebtWeightedAverageEffectiveInterestRate
0.21
CY2022Q4 emma Debt Weighted Average Effective Interest Rate
DebtWeightedAverageEffectiveInterestRate
0.20
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
25930000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
1763000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
2200000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
2321000
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
32214000
CY2022Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
32000
CY2022Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
84000
emma Warrants Granted Term
WarrantsGrantedTerm
P5Y
CY2022Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
500000
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.50
CY2023Q1 us-gaap Derivative Instruments And Hedges Liabilities
DerivativeInstrumentsAndHedgesLiabilities
85000
CY2022Q4 us-gaap Derivative Instruments And Hedges Liabilities
DerivativeInstrumentsAndHedgesLiabilities
70000
CY2023Q1 emma Gain Loss On Warrant Derivative Liabilities
GainLossOnWarrantDerivativeLiabilities
-14000
CY2023Q1 emma Warrants Granted Term
WarrantsGrantedTerm
P5Y
CY2023Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
7500000
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.50
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1200000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P3Y6M
CY2023Q1 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
49000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-103000
CY2023Q1 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2023Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
280000
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
303000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
785000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1063000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1092000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
836000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3776000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
692000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
3084000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2600000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
3100000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y6M
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.129

Files In Submission

Name View Source Status
emma-20230331_def.xml Edgar Link unprocessable
emma-20230331_cal.xml Edgar Link unprocessable
0000950170-23-021891-index-headers.html Edgar Link pending
0000950170-23-021891-index.html Edgar Link pending
0000950170-23-021891.txt Edgar Link pending
0000950170-23-021891-xbrl.zip Edgar Link pending
emma-20230331.htm Edgar Link pending
emma-20230331.xsd Edgar Link pending
emma-ex10_1.htm Edgar Link pending
emma-ex10_2.htm Edgar Link pending
emma-ex10_3.htm Edgar Link pending
emma-ex10_4.htm Edgar Link pending
emma-ex10_5.htm Edgar Link pending
emma-ex10_6.htm Edgar Link pending
emma-ex31_1.htm Edgar Link pending
emma-ex31_2.htm Edgar Link pending
emma-ex32_1.htm Edgar Link pending
emma-ex4_4.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img111184490_0.jpg Edgar Link pending
img111184490_1.jpg Edgar Link pending
img111184490_2.jpg Edgar Link pending
img111184490_3.jpg Edgar Link pending
img112108011_0.jpg Edgar Link pending
img112108011_1.jpg Edgar Link pending
img112108011_2.jpg Edgar Link pending
img112108011_3.jpg Edgar Link pending
img112108011_4.jpg Edgar Link pending
img112108011_5.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
emma-20230331_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
emma-20230331_pre.xml Edgar Link unprocessable
emma-20230331_htm.xml Edgar Link completed
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending